Brian Frenzel is a private investor and advisor to life science companies. His management experience includes co-founding and serving as CEO at Centaur Pharmaceuticals, a neurodegenerative disease pharmaceutical company (acquired by Renovis, NASDAQ: RNVS), Vesta Medical, a medical device company (acquired by Pfizer, NYSE:PFE), Adeza Biomedical, a specialty diagnostics company (NASDAQ:ADZA, acquired by Cytyc, NASDAQ:CYTC), and co-founder and COO/CFO of Genelabs Technologies, a biotechnology company (NASDAQ:GNLB). Prior to entering the startup company arena, Mr. Frenzel was the Director of Corporate Planning at Syntex Corporation, a Principal at Booz, Allen & Hamilton, a Consultant at the Boston Consulting Group and a Lieutenant in the United States Navy Nuclear Power Program. Mr. Frenzel holds a BS in physics and an MBA from Stanford University. Brian continues to be active in the pharmaceutical discovery and development arena, serving as interim CEO of Tosk, Inc., an oncology drug discovery and development company focusing on new drugs which block the adverse effects of existing chemotherapies and radiation therapy, Board member of SanBio, Inc. (TSE:4592), which develops cell therapies for recovery of function in patients suffering disability from neurodegenerative diseases such as stroke and traumatic brain injury; and an advisor to several early stage companies medical products companies.